EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 июл 2023 17:03:20 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces CEO Transition

27 июн 2023 06:55:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

15 май 2023 06:58:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

11 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For First Quarter 2023

09 май 2023 15:05:02 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

19 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

29 мар 2023 08:48:20 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 фев 2023 15:42:44 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 фев 2023 16:19:50 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 фев 2023 01:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 фев 2023 15:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 янв 2023 05:59:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 янв 2023 16:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 дек 2022 05:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 ноя 2022 05:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 ноя 2022 15:16:51 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 ноя 2022 15:05:14 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 окт 2022 05:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 сен 2022 15:12:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 сен 2022 05:30:00 Источник Nasdaq GlobeNewswire